News

News

Guerbet Announces Transition from Temporary Importation to Regular Supply for Lipiodol® (ethiodized oil) Injection; also introduces new glass vial container

1 April 2019
Read more...

Guerbet to present its innovative solutions offering for interventional imaging at CIRSE 2018

20 September 2018

Guerbet, the global specialist in contrast media and solutions for diagnostic and interventional medical imaging, has announced its presence at the 2018 annual congress of the CIRSE (Cardiovascular & Interventional Radiological Society of Europe), to be held from September 22 to 25, 2018 in Lisbon (Portugal).

Read more...

New indication approved for Guerbet’s Lipiodol® Ultra Fluid

11 September 2018

Guerbet announced today that it has been granted approval for a new indication for Lipiodol® Ultra Fluid in Belgium, Ireland, Portugal, Hong-Kong and the Philippines, for selective hepatic intra-arterial injection for visualization, localization and vectorization during conventional trans-arterial chemoembolization (cTACE) of tumors in adults with known, intermediate-stage hepatocellular carcinoma (HCC).

 

Read more...

Guerbet announces the acquisition of a new microsphere technology to strengthen its interventional imaging range

26 April 2018

• Acquisition of a technology developed by Occlugel, a French company specialized in the R&D of microspheres used in embolization;

• This new technology will round out Guerbet’s Interventional Imaging solutions and create synergies with the Accurate range of anti-reflux microcatheters.

Read more...

Guerbet announces its partnership with Lausanne’s CHUV and CET to launch a clinical study

13 April 2018

Guerbet announces its partnership with Lausanne’s CHUV and CET to launch a clinical study aimed at evaluating the activating effects of Lipiodol®-based conventional transarterial chemoembolization (cTACE) on the immunity of patients with hepatocellular carcinoma (HCC)

▪ HCC is the second leading cause of cancer mortality worldwide

▪ Evaluation of the immunogenic potential of cTACE

Read more...

GUERBET to present its solutions offering at the ECIO in Vienna, Austria from 22 to 25 April 2018

11 April 2018
  • A major event, the ECIO brings together international interventional oncology experts every year
  • Organization of a symposium “New perspectives in cTACE to improve the treatment of HCC patients” on April 23 from 13:45 to 14:30.

Villepinte (France), April 11, 2018 (6:00 PM CEST) – Guerbet (FR0000032526 GBT), the global specialist in contrast media and solutions for medical imaging, will present its interventional imaging solutions offering at the ECIO (European Conference on Interventional Oncology) in Vienna, Austria from April 22 to 25, 2018.

Read more...

Guerbet announces its acquisition of Accurate Medical Therapeutics

8 January 2018

Guerbet announces its acquisition of Accurate Medical Therapeutics, an innovative company that develops microcatheters for interventional radiology

  • Acceleration of the interventional radiology strategy
  • Acquisition of a unique technology for image-guided embolization procedures

Villepinte (France), January 8, 2018 (17:45 CET) – Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announced that it has entered into an agreement under which it will acquire Israeli company Accurate Medical Therapeutics (“Accurate”), which specializes in the development of microcatheters used in interventional radiology.

Read more...

Join us at RSNA 2017 to discover our diagnostic and interventional imaging solutions!

23 November 2017

RSNA 2017 ӏ Guerbet Booth #1341 – South Building – Hall A ӏ November 26 to December 1 ӏ McCormick Place ӏ Chicago, USA

Imaging professionals are warmly invited to meet up with Guerbet at RSNA 2017, the annual Radiological Society of North America congress. The event organizer will focus this year on the theme: “Innovation in radiology as a means of creating positive impact on patient care”.

SNA2017 on social media.

Read more...

Guerbet to take part in the 65th edition of the Journées Francophones de Radiologie Diagnostique et Interventionnelle (JFR)

9 October 2017

> Organization of two symposiums on October 13 and 14
> Presentation of Vectorio®, an innovative medical device, at the “Interventional Radiology Village”

Villepinte (France), October 9, 2017 (8:30 CEST) – Guerbet (FR0000032526 GBT), the global specialist in contrast products and solutions for medical imaging, today announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will be held in Paris from October 13 to 16, 20171.

Read more...

CIRSE 2017: new developments for interventional radiologists

15 September 2017

CIRSE 2017 │ from September 16 to 20, 2017 │ Bella Center │ Copenhagen (Denmark)

The most important congress in interventional radiology, CIRSE 2017 (Cardiovascular & Interventional Radiological Society of Europe), will open its doors in Copenhagen on September 16. Guerbet will be there and our teams will be delighted to present you our innovative solution in interventional radiology and Theranostic. The Group will also showcase its global Cath Lab offer with its dedicated injector, and its X-Ray digital solution.

On Monday, September 18th, we look forward to seeing you at our Satellite Symposium (13:00, Auditorium 2) titled “Liver cancer & lymphatic disorders, therapy evolutions for patient benefit”, which will be chaired by Prof. Valérie Vilgrain (Hôpital Beaujon, France).

At the CIRSE 2017, Guerbet will launch a solution dedicated to interventional radiologists and will provide interactive demonstrations at its Learning Center. Do not miss this opportunity and come and meet our experts!

Find more information on http://www.cirse.org/ and on the social networks with the CIRSE Facebook page and hashtag #CIRSE2017 on Twitter.

Read more...

We use cookies to improve your website experience and to gain insights into our websites’ users and traffic to make it even better. By continuing your navigation on our site without modifying the setting of your cookies, you accept the use of cookies. OKFind out more